



HOUSE COMMITTEE ON APPROPRIATIONS

FISCAL NOTE

HOUSE BILL NO. 2211

PRINTERS NO. 3665

PRIME SPONSOR: Ward

COST / (SAVINGS)

FUND	FY 2017/18	FY 2018/19
General Fund	\$0	\$0

SUMMARY: House Bill 2211, Printer's Number 3665, establishes the Consumer Prescription Drug Pricing Disclosure Act to expand the ability of pharmacists to provide cost-related prescription drug information to patients. This legislation is effective in 60 days.

ANALYSIS: HB 2211 allows pharmacies and pharmacists to provide a covered individual with information concerning the cost of a prescription drug, including the individual's cost share. Under the legislation, a pharmacy benefits manager (PBM) may not prohibit or penalize a pharmacist, pharmacy or its contracting agent from doing the following:

- disclosing available information concerning the cost of a prescription drug to a covered individual, including the individual's cost share;
- disclosing the availability of any therapeutically equivalent alternative medication; or
- selling to the covered individual a more affordable alternative if such an alternative is available.

FISCAL IMPACT: Enactment of this legislation should have no adverse fiscal impact on Commonwealth funds.

PREPARED BY: Ann Bertolino
House Appropriations Committee (R)

DATE: June 22, 2018

Estimates are calculated using the best information available. Actual costs and revenue impact incurred may vary from estimates.